Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

PharmAkea, Celgene extend collaboration
January 2017
SHARING OPTIONS:

SAN DIEGO—PharmAkea Inc. has extended its strategic collaboration with Celgene Corp., a three-year deal originally established in October 2013. The deal was struck to apply PharmAkea’s proprietary drug discovery platform and novel small-molecule therapies targeting fibrotic diseases. Per the terms of the extension, Celgene has committed $9 million to extend the deal for nine months. PharmAkea is conducting a Phase 1 SAD and MAD trial and toxicology studies that will enable Phase 2 trials of its lead program, a small-molecule LOXL2 inhibitor, as well as IND-enabling studies to prepare for a Phase 1 trial of its second program, an autotaxin inhibitor.
 
“We have been very impressed with the progress the team at PharmAkea has made over the past three years,” remarked Rupert Vessey, Celgene’s president of Research and Early Development. “This extension allows the company to further realize the potential of their programs and to complete some key activities.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.